Aims: To evaluate the evidence of the effectiveness and safety of Chinese herbal medicine skin-patches for patients with acute gouty arthritis.
| INTRODUCTION
Gouty arthritis has been as one of the most common causes of inflammatory arthritis in the global range (Roddy & Doherty, 2010 ).
Acute gouty arthritis can limit the daily activity of patients (Neogi, 2011) and also severely impair patients' quality of life (Becker et al., 2009; Lee et al., 2009; Roddy, Zhang, & Doherty, 2007) . Though many effective therapies are developed to release the acute symptoms by western medicine, there is still growing interest in complementary therapies for its advantages. Skin-patch of Chinese Herbal Medicine (CHM) has shown promising efficiency in curing acute gouty arthritis (Chen, Wu, & Zhang, 2011; Wu & Gao, 2010) . As an indispensable member of treatment team, nurses play a crucial role in improving the life quality of these patients through providing frontline general support. Therefore, nurses should be provided with evidence-based information about the effect and safety of skinpatch of CHM in treating acute gouty arthritis. Nurses administer skin-patches to patients with acute gouty arthritis in most hospitals in China . To satisfy the demands of nurses, we conducted a systematic review and meta-analysis study to evaluate the efficiency and safety of skin-patch with CHM for acute gouty arthritis.
| Background
Acute gouty arthritis is caused by the deposition of uric acid in the joints as the serum uric acid level increases (Richette & Bardin, 2010; Wortmann, 2002) and is characterized by the sudden onset of intense pain and swelling of one or more joints (Terkeltaub, 2010) .
Based on epidemiological studies conducted in different areas and at different times, its prevalence has increased in recent years (Chang, Matthew, Zhang, & Doherty, 2015; Juraschek, Miller, & Gelber, 2013; Lu, Cui, & Li, 2015; Miao et al., 2008; Nan et al., 2006; Shao, Xu, & Mo, 2004; Yan et al., 2011) .
There are many kinds of therapy for acute gouty arthritis in Western medicine. The principal goals of therapy for acute gout are the symptomatic treatment of the acute inflammation of the affected joint, such as relieving the pain and swelling and improving the mobility of the joint (Richette et al., 2016) . The American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) guidelines for the pharmacologic management of acute gouty arthritis include administration of oral colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and interleukin (IL)-1 blockers. However, each of these agents is associated with the risk of potentially severe adverse effects (AEs) such as gastrointestinal and cardiovascular problems and drug-drug interactions, particularly in elderly patients and in individuals with comorbidities such as chronic kidney disease (CKD). These risks restrict the long-term use of these treatments (Hamburger et al., 2011; Khanna et al., 2012) .
In China, skin-patches of CHM, based on the theory of traditional Chinese medicine (TCM), are one of the most popular therapies for the treatment of acute gouty arthritis due to their convenience and low rate of AEs. Some clinical studies have demonstrated that skin-patches of CHMs benefit patients with acute gouty arthritis.
To date, no guidelines have recommended skin-patches of CHMs for acute gouty arthritis. However, many clinical studies have reported the promising effects of skin-patches of CHM on acute gouty arthritis.
Three relative systematic reviews have been identified (Tong, Ma, & Chen, 2013; Wu, 2014a Wu, , 2014b . All of these studies were published in Chinese. Tong's study analysed the herbs most frequently used in topical applications of traditional Chinese medicine, and there was little useful information available. Wu (2014a) evaluated effect and safety of skin-patch of CHM combined with western medicine for
Why is this research/review needed?
People with acute gouty arthritis, especially those with a serious case, require more effective treatments.
Skin-patches of Chinese herbal medicine are commonly used in China as supplementary therapy for patients with acute gouty arthritis; many clinical studies have reported promising effects.
There is evidence to support the efficacy of this treatment, but confirmatory evidence is necessary. Further exploration of the specific function of the therapy is also necessary, as is additional safety information.
What are the key findings?
Skin-patches of Chinese herbal medicine combined with Western medicine seemed to be more effective than Western medicine alone to reduce the pain scores of patients with acute gouty arthritis.
The current available evidence is of low quality. Some recommendations for future research are proposed.
The decision of whether to administer skin-patches of Chinese herbal medicine should consider the current available evidence and the individual patient's condition.
How should the findings be used to influence policy/practice/research/education?
The review showed that skin-patches of Chinese herbal medicine may be effective, especially for pain relief from acute gouty arthritis. This potentially useful treatment requires further investigation.
More large-scale and high-quality randomized controlled trials of skin-patches of Chinese herbal medicine are needed.
More studies of the effect of skin-patches of Chinese herbal medicine on the quality of life of patients with acute gouty arthritis are needed. The adverse effects associated with the use of topical herbal treatments should also be investigated. acute gouty arthritis. Wu (2014b) summarized the evidence of external application (including fumigation, washing, steaming, skin-patch) with CHM for acute gouty arthritis. Also, they had some limitations: (1) the search strategies were not adequately detailed; (2) the outcome measures that were evaluated did not directly demonstrate the function of the therapy and ignored other patient-concerned outcomes (such as QOL); and (3) all study results were synthesized without considering the heterogeneity of the studies.
Our review adapted a more comprehensive search strategy and focused on clinical outcomes that were globally acknowledged to describe the characteristics of acute gouty arthritis. To analyse heterogeneity, we also conducted subgroup analyses based on the different interventions used by the control groups.
| THE REVIEW

| Aims
Randomized controlled trials that compared skin-patches of CHM with or without conventional treatment to conventional treatment, no treatment, or a placebo treatment of patients with acute gouty arthritis were reviewed to examine the effectiveness and safety of skin-patches of CHM with or without conventional treatment. This review addressed the following questions:
1. Are skin-patches of CHM more effective than a placebo treatment or conventional medicine to relieve pain or improve the function of the target joints of patients with acute gouty arthritis? 2. Are skin-patches of CHM more effective than a placebo treatment or conventional medicine to decrease the serum uric acid (SUA) level and control inflammation?
3.
Are skin-patches of CHM a safe treatment?
| Design
A systematic review and meta-analysis was conducted using the principles and processes in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins & Green, 2011) .
| Search methods
This systematic review was registered in the International Prospective Register of Systematic Reviews (CRD42017055179) and was reported following the Preferred Reporting for Systematic Reviews and Meta-Analysis (PRISMA) Statement (Moher, Altman, Liberati, & Tetzlaff, 2011 used: "arthritis, gouty," "gout," "tongfeng," "hyperuricemia," "uric acid,"
"tophi"; "administration, topical," "administration, cutaneous," "external application," "topical application," "external therapy," "topical therapy," "topical," "external," "compress," "stick," or "paste"; and "Chinese medicant," "Chinese herbal medicine", "herbs", "herbalism", "drugs, Chinese herbal" or "medicine, Chinese traditional". We also searched the reference lists of the retrieved articles.
| Types of studies
Randomized controlled trials (RCTs), including published and unpublished trials, that tested the effectiveness and safety of skin-patches of CHM in patients with acute gouty arthritis were eligible. We required studies to include human participants and to present original data.
| Participants
Patients were 18 years of age or older and had been diagnosed using the EULAR criteria or the American Rheumatism Association preliminary classification criteria for acute gout (Holmes, 1985; Wallace et al., 1977) .
| Interventions
We defined an intervention as any dosage of traditional CHM for 
| Outcome measures
Trials that measured one or more of the following measurable outcomes were included (Nicola et al., 2014; Schumacher et al., 2009; Taylor, Schumacher, Singh, Grainger, & Dalbeth, 2007) .
The primary outcome measures were as follows: The secondary outcome measures were as follows:
1. Clinical effectiveness, as assessed by a change in the SUA levels after treatment.
2.
Changes in the white blood cell (WBC) count, C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR).
3. Inflammation, scored as tenderness or swelling of the joint.
4.
Safety was assessed by the counted number of AEs, such as cutaneous anaphylaxis and serious AEs, or treatment withdrawal (due to the lack of effectiveness or because of AEs) after starting the intervention.
| Search outcomes
The flow chart in Figure 1 
| Quality appraisal
The quality of eligible studies was assessed using the risk of bias tools from the Cochrane Handbook, Version 5.1.0 (Higgins & Green, 2011) . The criteria primarily included random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other sources of bias (sample size estimate, clear inclusion and exclusion criteria, funding, conflicts of interest and potential bias related to the specific study design). Each item was assessed as "low risk", "unclear risk" or "high risk." The quality of each eligible trial was classified into the following three levels: "high risk of bias" (at least one item was classified as high risk), "low risk of bias" (all items were classified as low risk) or "unclear risk of bias" (at least one item was classified as unclear risk). Two authors in the current study independently assessed the risk of bias of each study and then compared their results. Disagreements regarding a risk of bias assessment were settled by discussion and consensus with two other authors of this study.
| Data abstraction
Two other authors extracted the data independently. Information including the first author, year of publication, characteristics of the participants, each trial's inclusion and exclusion criteria, the total number of cases included in the experimental and control groups, intervention methods and endpoint evaluation indicators was extracted. Any discrepancies were negotiated and resolved based on the original article or by a third author. We contacted three authors to request additional information.
Two responded, but only one provided useful information.
| Synthesis
Two authors independently conducted the data analysis using RevMan V.5.3 (Cochrane Collaboration, London, UK) software. Continuous data were expressed as the mean difference (MD) with 95% confidence intervals (CIs). The pain scores and swelling of the affected joints were assessed using different measurement scales in different studies, so a standardized mean difference (SMD) was calculated. The differences between the treatment groups and control groups were considered significant at p < .05. The Higgins I 2 test was used to determine heterogeneity prior to the meta-analysis to determine if the included studies contained inconsistencies. An I 2 statistic >50% indicated significant heterogeneity among the studies.
Thus, the random effects model was applied.
Subgroup analysis, which was pre-specified, was performed according to the different Western therapies administered to the control groups due to the different pharmacological actions of different drugs and our clinical experiences. There was not a sufficient number of studies (n ≥ 10) of each outcome, so publication bias could not be analysed using a funnel plot.
| RESULTS
| Characteristics of the trials
A total of 19 trials with 1,636 participants were included in this systematic review. All 19 trials were conducted in China and were published in Chinese. Eighteen studies included 1,546 participants and reported the sex ratio; there were 1,306 male participants and 186 female participants. Only one study, which included 90 participants, did not report the sex ratio (Zhou, Li, Ye, & Jia, 2015) . Eighteen trials had two arms; one trial had three arms (Wang, 2015) . One trial reported information on study withdrawals (Wang, 2015) ; six participants withdrew due to pain intolerance. Fifteen trials reported the trial setting. All patients were outpatients or inpatients.
Among the 19 trials, eight used an experimental treatment of skin-patches of CHM alone and 12 evaluated skin-pastes of CHM combined with routine treatments in the experimental group. Routine treatments included oral sodium bicarbonate (NaHCO 3 ), colchicine, NSAIDs and allopurinol, used alone or in combination. (Table 1) .
| Methodological quality
Eight of the 19 RCTs reported the method of sequence generation.
Seven trials referred to a random number table and one trial used PASW Statistics for Windows, Version 18.0 (SPSS Inc., Chicago, IL, USA). One trial used envelopes and one trial used blocked randomization for allocation concealment. Therefore, 17 trials had an unclear risk for allocation concealment. Nineteen trials did not use a blinding method with a high risk for blinding participants and personnel because it could be difficult to create a placebo similar to the Chinese medicinal application. The outcome measurement could be influenced by the lack of blinding. Only one trial provided specific information on the blinding of outcome assessment: the investigators were divided into three groups and the outcome evaluators were blinded to avoid detection bias (Wang, 2015) . Therefore, we classified that study as low risk. For the other trials, the outcomes were objective outcome measures such as the SUA, ESR, or CRP level and WBC count and were regarded as low risk. High-risk trials were trials where the outcomes were assessed subjectively, such as the assessment of pain control using the VAS, NRS, or time to the first evidence of meaningful relief and average time to complete relief, Records identifed through database searching (N = 1113) Duplicated moved records (N = 593)
Records screened (N = 520) 376 records were excluded; 65 were not relevant studies; 236 were irrelevant interventions; 13 were not relevant comparisons; 6 were not in the flares; 55 were not RCTs; 1 was case report 32 inclued improper interventions; 7 used improper comparisons; 24 used improper diagnostic criteria; 45 reported outcomes that did not meet the criteria; 9 were not of a completely randomized design; 4 had unclear treatment of the control group; 1 used participants who were not eligible; 3 had unclear basic information on the participants function of the target joint assessed by NRS and health-related quality of life. One trial reported withdrawal, which may have affected the results. Thus, it was considered to have a high risk of attrition bias.
Other trials were classified as low risk. One trial did not report a primary outcome in the outcome measures in advance and did not report three secondary outcomes in the results (Zhou, 2009 ). Therefore, it was classified as high risk. The other trial was assessed as an unclear risk, as it did not report the outcome measures (Chen et al., 2011) .
The remaining trials all reported outcomes in their results in accordance with the outcome measures described in their methods, and all were assessed as low risk. For other types of bias, 16 trials did not describe the sample size estimate, funding, or conflicts of interest.
Thus, they were all assessed as having an unclear risk. Three trials were estimated as high risk due to their study design (Figure 2 ).
| Effects estimates
We conducted subgroup analyses of different conventional medications.
| Pain relief
Time of first effective relief (hours)
In comparison 1 (skin-patch of CHM + co-intervention vs. co-intervention), the first effective relief time of the experimental treatment was shorter than that of the control treatment of NSAIDs (N = 123; mean difference, À5.24; 95% CI, À6.89 to À3.59) and was not significantly different than that of the control treatment of colchicine + NaHCO 3 (Figure 3 ). There were no related studies that used the outcome of comparison 2 (skin-patch of CHM vs. cointervention).
Pain score
In comparison 1, a subgroup meta-analysis (Figure 4) showed that the pain scores of the experimental group may have been reduced more effectively than the pain scores of the groups using NaHCO 3 + NSAIDs (N = 132; standardized mean difference, À0.98; 95% CI, À1.68 to À0.28) and colchicine (N = 306; standardized mean difference, À0.98; 95% CI, À1.30 to À0.92). In comparison 2, due to the significant heterogeneity, no meta-analysis was conducted ( Figure 5 ).
One study showed that skin-patches of CHM can reduce the pain score more effectively than NSAIDs and one showed that skinpatches of CHM can reduce pain scores more effectively than NSAIDs + allopurinol.
Duration of complete relief (day)
In comparison 1, there were no related studies with this outcome. In comparison 2, no subgroup meta-analysis was conducted ( Figure 6 ).
One study (Zhou, 2009 ) demonstrated that the CHM skin-patches had a shorter duration of complete relief than NSAIDs; the other (Huang, Long, & Yang, 2005) showed that CHM skin-patches had a shorter duration of complete relief than treatment with NSAIDs + allopurinol.
| Function limitations of relief after treatment
In comparison 1, there were no related studies with this outcome. In À1.01 to À0.09) showed that the use of skin-patches of CHM can improve joint function more effectively than NSAIDs (Figure 7 ).
| Quality of life
In comparison 1, only one trial (Wang, 2016) assessed the QOL using the HAQ-DI and compared skin-patches of CHM + colchicine with colchicine alone. In comparison 2, only one study (Shi, 2011) assessed the QOL; it used the SF-36 and compared skin-patches of CHM to NSAIDs. There was no statistical difference between the two groups.
| SUA level
In comparison 1 (Figure 8 ), due to the significant heterogeneity, no meta-analysis was conducted. Two thirds of the studies showed that the experimental treatment reduced the SUA level more effectively than the control treatments. In comparison 2 (Figure 9 ), a meta-analysis (N = 247; MD, 7.67; 95% CI, À9.66 to 25.01) was conducted (Huang et al., 2005; Lin, 2013; Xu, Zheng, & Zhu, 2010) , which
showed that treatment with skin-patches of CHM was not superior to treatment with NSAIDs + allopurinol. In addition, we temporarily omitted the results of one study (Huang et al., 2005 ) through Non-steroidal anti-inflammatory drugs (NSAIDs), the control group received only NSAIDs; Colchicine + NaHCO 3 , the control group received colchicine and NaHCO 3 ; Experimental, the group was treated using skin-patches of CHM; Control, the group was treated using Western medicine. (3) F I G U R E 4 Effects of skin-patches of Chinese herbal medicine on pain scores of patients with acute gouty arthritis.
(1) Study groups, first author and year of publication. (2) Subgroups were divided by treatment, as follows: Colchicine, the control group was treated only with colchicine; NaHCO 3 + non-steroidal anti-inflammatory drugs (NSAIDs), the control group was treated with NaHCO 3 and NSAIDs; Experimental, the group was treated with skin-patches of Chinese herbal medicine; Control, the group was treated with Western medicine. | 1777 sensitive analysis. Thus, an additional meta-analysis was performed (N = 200; MD, 11.34; 95% CI, 1.87-20.80), which showed that the results were stable. Other trials (Wang, 2015; Zhou & Gu, 2016 ) also showed that skin-patches of CHM were not superior to conventional treatments. F I G U R E 5 Effects of skin-patches of Chinese herbal medicine on the pain scores of patients with acute gouty arthritis. (1) Study groups, first author and year of publication. (2) Subgroups were divided by treatment, as follows: non-steroidal anti-inflammatory drugs (NSAIDs), the control group was treated with NSAIDs; NSAIDs + allopurinol, the control group was treated with allopurinol and NSAIDs; Experimental, the group was treated with skin-patches of Chinese herbal medicine; Control, the group was treated with Western medicine. (3 F I G U R E 6 Effects of skin-patches of Chinese herbal medicine on the time of complete relief (days) in patients with acute gouty arthritis.
| Inflammation control after treatment
(1) Study groups, first author and year of publication. (2) Subgroups were divided by treatment, as follows: Non-steroidal anti-inflammatory drugs (NSAIDs), the control group was treated with only NSAIDs; Allopurinol + NSAIDs, the control group was treated with both allopurinol and NSAIDs; Experimental, the group was treated with skin-patches of Chinese herbal medicine; Control, the group was treated with Western medicine. Figure 10) . The meta-analysis of two studies (Chen, 2016; Fan, Ma, Pei, & Cui, 2016) showed that the experimental treatment was more effective than treatment with NSAIDs (N = 143; MD, À2.72; 95% CI, À3.82 to À1.62). In comparison 2, one trial shwed that skin-patches of CHM were not superior to NSAIDs (N = 100; MD, À4.1; 95% CI, À5.63 to À2.57).
ESR
In comparison 1, with the exception of one trial (Chen et al., 2011) , all studies found that the experimental treatment was more effective than the control treatment ( Figure 11 ). Only one subgroup conducted a meta-analysis (N = 159; MD, À5.34; 95% CI, À10.94 to 0.27) and it showed that the experimental treatment was not superior to colchicine treatment. In comparison 2, none of the trials showed a significant difference between groups (Figure 12 ).
Joint swelling assessed using an NRS
In comparison 1, one trial (Zhou et al., 2015) showed that joint swelling was more effectively reduced in the experimental group than in the control group (NSAIDs: N = 90; SMD, À1.55; 95% CI, À2.02 to À1.07). In comparison 2 (Figure 13 ), due to the significant heterogeneity, no meta-analysis was conducted. All studies showed a significant difference between groups.
No studies reported the WBC.
| Safety issues
In comparison 1 (Figure 14) , the meta-analysis showed that the herbal paste + co-intervention group had fewer adverse events than the co- 
| Herbs frequently used in topical applications for acute gouty arthritis
Nineteen studies reported the use of herbs and decoctions for external use. The most frequently used herbs in topical applications for acute gouty arthritis were dahuang (Rhei radix et rhizoma), huangbai (Cortex Phellodendri), jianghuang (Rhizoma Wenyujin Concisum) and tiannanxing (Arisaema erubescens Schott) ( Table 2 ).
| Publication bias
Publication bias could not be analysed by a funnel plot analysis because sufficient studies (n ≥ 10) did not exist for any outcome.
| DISCUSSION
| Principle findings
Nineteen RCTs conducted in China were included in this systematic review, which contained two comparisons. We determined from the meta-analysis that, first, the skin-patches of CHM combined with
Western medicine (NSAIDs + NaHCO 3 /colchicine) seemed to more F I G U R E 8 Effects of skin-patches of Chinese herbal medicine on the serum uric acid (SUA) levels of patients with acute gouty arthritis. (1) Study groups, first author and year of publication. (2) Subgroups were divided by treatment, as follows: NSAIDs, the control group received non-steroidal anti-inflammatory drugs (NSAIDs); NaHCO3 + NSAIDs, the control group was treated with both NaHCO 3 and NSAIDs; Colchicine, the control group was treated with colchicine; Colchicine + allopurinol, the control group was treated with colchicine and allopurinol; Colchicine + NaHCO 3 , the control group received colchicine and NaHCO 3 ; Experimental, the group was treated with skin-patches of Chinese herbal medicine; Control, the group was treated with Western medicine. | 1779 effectively reduce pain scores than Western medicine alone. Second, the effect on the SUA level of skin-patches of CHM combined with Western medicine or skin-patches alone was unclear, since the Western treatments used by the control group do not decrease the SUA level. Third, only two trials assessed the QOL of the included patients, so there is still insufficient evidence to identify the effect of CHM skin-patches on QOL. Fourth, the adverse reactions of skin-patches of CHM seemed to be fewer than those of the Western treatments.
| Limitations of this systematic review
However, the beneficial findings must be interpreted cautiously.
First, all included articles were published in Chinese and their methodology was determined to have a high risk of bias, including poor randomization, poor allocation concealment and absence of blinding. Most trials did not report the details on randomization and concealment, which may contribute to potential bias and an overestimated effect of the intervention (Kjaergard, Villumsen, & Gluud, 2001 ). This may have something to do with the situation that skinpatches of CHM are a supplementary or adjuvant treatment for acute gout and are somewhat neglected, especially compared with routine treatments. Thus, firm conclusions cannot be drawn.
No placebo-controlled trial was identified, which may lead to exaggeration of the effectiveness of the intervention. The use of a placebo is necessary to evaluate the efficacy of an intervention curing an acute and self-resolving disease (which is known as the placebo effect), especially for pain assessments (Hr objartsson & Gøtzsche, 2010) . However, we admit that it is hard to make a placebo that can mimic the smell of CHM, so it may be a challenge to use double or single blinding.
Only two studies reported patient-concerned outcomes such as QOL, which can reveal more potential benefits of skin-patches of CHM. More studies that include QOL as an outcome are necessary.
Further investigation of safety issues is still necessary. Based on the limited data, the most common symptom was a minor allergic skin rash. Whether this treatment can also cause severe allergic reactions related to the patient's tolerance is not known, so the threat to life also remains unclear.
Second, the heterogeneity of the included studies was significant. The subgroups that used Western medicine ingredients made it impossible to include some studies in the meta-analysis. There may be other potential subgroup factors based on other studylevel characteristics, such as the baseline of the included trials, course of gout and treatment course. We conducted a subgroup F I G U R E 9 Effects of skin-patches of Chinese herbal medicine on the serum uric acid (SUA) levels of patients with acute gouty arthritis.
(1) Study groups, first author and year of publication. (2) Subgroups were divided by treatment, as follows: Allopurinol + non-steroidal antiinflammatory drugs (NSAIDs), the control group was treated with both allopurinol and NSAIDs; NSAIDs, the control group was treated with NSAIDs; NSAIDs + NaHCO 3 , the control group was treated with both NSAIDs and NaHCO 3 ; Experimental, the group was treated with skinpatches of Chinese herbal medicine; Control, the group was treated with Western medicine. Third, due to the language barrier, we only searched databases in Chinese and English, though articles in other language were also considered if accompanied by an English abstract. However, it is possible that relevant studies were omitted from this analysis.
| Comparison to previous studies
We identified three similar systematic reviews. Tong et al. published a systematic review to analyse the most frequently used herbs in topical applications of traditional Chinese medicine (Tong et al., 2013 ), but did not provide detailed information about the search strategy or the included studies. Our results on the frequency are congruent with those of Tong et al., which might demonstrate that the selection of herbs for skin-patches of CHM to treat acute gouty arthritis has remained stable in recent years. For the remaining reviews, one was a published study (Wu, 2014a) and the other was a Ph.D. dissertation (Wu, 2014b) . The beneficial result is that skin-patches of CHM combined with
Western medicine (NSAIDs + NaHCO 3 /colchicine) seemed to be more effective than Western medicine alone for the reduction of pain scores. The result of skin-patches of CHM alone compared with
Western medicine seemed to be unclear due to the insufficient number of trials.
| Implications for future research
According to the defects of the included trials, we have the following suggestions for future research:
Heterogeneity: 2 = 0.00; τ χ 2 = 0.76, df = 1 (p = .38); I 2 = 0% (1) Study groups, first author and year of publication. (2) Subgroups were divided by treatment, as follows: non-steroidal anti-inflammatory drugs (NSAIDs), the control group was treated with NSAIDs; Allopurinol + NSAIDs + NaHCO 3 , the control group was treated with allopurinol, NaHCO 3 and NSAIDs; Colchicine, the control group was treated with only colchicine; Colchicine + NaHCO 3 , the control group was treated with both colchicine and NaHCO 3 ; Experimental, the group was treated with skin-patches of Chinese herbal medicine; Control, the group was treated with Western medicine. (3) I 2 and P are the criteria of the heterogeneity test [Colour figure can be viewed at wileyonlinelibrary.com]
1. Registration should be completed before the trial starts. Reporting the registration number could help reduce the publication bias and understand the selective reporting information. Sample calculations should be performed before the study begins.
2.
The methodology of clinical trials should be improved. To confirm the findings of the current review, specific methods of randomization and strict allocation concealment are needed and it is also operational. Although the use of double or single blinding is still F I G U R E 1 1 Effects of skin-patches of Chinese herbal medicine on the erythrocyte sedimentation rate (ESR) of patients with acute gouty arthritis.
(1) Study groups, first author and year of publication. (2) Subgroups were divided by treatment, as follows: non-steroidal antiinflammatory drugs (NSAIDs) + NaHCO 3 , the control group was treated with both NSAIDs and NaHCO 3 ; Colchicine, the control group was treated with only colchicine; Allopurinol + colchicine, the control group was treated with both allopurinol and colchicine, NaHCO 3 and NSAIDs; Colchicine + NaHCO 3 , the control group was treated with both colchicine and NaHCO 3 ; Experimental, the group was treated with skinpatches of Chinese herbal medicine; Control, the group was treated with Western medicine. F I G U R E 1 2 Effects of skin-patches of Chinese herbal medicine on the erythrocyte sedimentation rate (ESR) of patients with acute gouty arthritis. (1) Study groups, first author and year of publication. (2) Subgroups were divided by treatment, as follows: non-steroidal antiinflammatory drugs (NSAIDs), the control group was treated with NSAIDs; Allopurinol + NSAIDs, the control group was treated with allopurinol and NSAIDs; NSAIDs + NaHCO 3 , the control group was treated with NSAIDs and NaHCO 3 ; Experimental, the group was treated with skin-patches of Chinese herbal medicine; Control, the group was treated with Western medicine. 
| Implications for nursing
Nurses should be clearly informed of the possible beneficial and adverse effects of skin-patches of CHM when making recommendations for treatments, as doctors, nurses and patients may be included in the decision-making on whether to administer topical herbal medicine. To achieve the best clinical outcome, the joint efforts of the entire care team are required (Hung et al., 2015 F I G U R E 1 3 Effects of skin-patch of Chinese herbal medicine on swelling of joints assessed by numeric rating scale in patients in acute gouty arthritis. (1) Study of groups, first author and publish year; (2) subgroups divided by western medicine ingredients: Allopurinol +NSAIDs, the control group both only contained allopurinol and NSAIDs; NSAIDs, the control group only contained NSAIDs; Experimental, the group of skin-patch of Chinese herbal medicine; Control, the group of western medicine. (3 
| CONCLUSIONS
Based on the results of this meta-analysis, skin-patches of CHM combined with Western medicine seemed to more effectively relieve pain than Western medicine alone. Skin-patches of CHM had fewer side effects than Western medicine. They may be used as adjunct therapy to the conventional interventions to relieve pain. However, due to the generally low methodological quality and poor reporting of the included studies, our conclusions are necessarily cautious and must be confirmed by additional studies.
